Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Net Cash Flow (2016 - 2026)

Lexaria Bioscience's Net Cash Flow history spans 12 years, with the latest figure at $826273.0 for Q1 2026.

  • Quarterly results put Net Cash Flow at $826273.0 for Q1 2026, up 154.57% from a year ago — trailing twelve months through Feb 2026 was -$1.4 million (down 175.42% YoY), and the annual figure for FY2025 was -$4.6 million, down 189.93%.
  • Net Cash Flow for Q1 2026 was $826273.0 at Lexaria Bioscience, down from $2.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $3.8 million in Q2 2024 to a low of -$2.8 million in Q3 2025.
  • The 5-year median for Net Cash Flow is -$1.3 million (2023), against an average of -$264628.6.
  • The sharpest move saw Net Cash Flow surged 3570.48% in 2024, then tumbled 154.54% in 2025.
  • Year by year, Net Cash Flow stood at -$1.3 million in 2022, then surged by 146.69% to $597691.0 in 2023, then skyrocketed by 164.61% to $1.6 million in 2024, then surged by 57.12% to $2.5 million in 2025, then tumbled by 66.75% to $826273.0 in 2026.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $826273.0, $2.5 million, and -$2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.